Lung Cancer

First potentially clinically useful independent marker identified

Published in Cancer Weekly, December 17th, 2002

Research by U.S. scientists has produced a novel finding about the effect on cancer of an important DNA repair gene and, as a result, identified the first clinically useful independent prognostic marker for early-stage resected patients with non-small-cell lung cancer.

Their results should help doctors in the future to determine which of their patients with non-small cell lung cancer (NSCLC) who have undergone surgery with curative intent are likeliest to suffer from recurrences or relapse of their cancer. Consequently, postsurgery treatments used to prevent recurrences or relapse of their cancer could potentially be targeted to this group of high-risk individuals. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-12-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry